Danaher Co. (NYSE:DHR) Shares Sold by Fortitude Family Office LLC

Fortitude Family Office LLC lowered its holdings in Danaher Co. (NYSE:DHR) by 70.4% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 407 shares of the conglomerate’s stock after selling 970 shares during the quarter. Fortitude Family Office LLC’s holdings in Danaher were worth $113,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Claro Advisors LLC acquired a new position in Danaher during the first quarter worth about $255,000. Azzad Asset Management Inc. ADV grew its holdings in shares of Danaher by 0.5% in the 1st quarter. Azzad Asset Management Inc. ADV now owns 11,586 shares of the conglomerate’s stock worth $2,893,000 after acquiring an additional 62 shares during the period. Redmont Wealth Advisors LLC purchased a new position in Danaher in the 1st quarter valued at approximately $30,000. Norden Group LLC acquired a new position in Danaher during the first quarter worth $4,151,000. Finally, Advisor Resource Council acquired a new stake in Danaher in the first quarter valued at $260,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Buying and Selling

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Danaher news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Matthew Mcgrew sold 16,172 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the sale, the chief financial officer now owns 29,407 shares of the company’s stock, valued at approximately $8,229,254.88. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 21,052 shares of company stock valued at $5,878,937. 11.10% of the stock is currently owned by corporate insiders.

Danaher Price Performance

Danaher stock opened at $242.78 on Wednesday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The company has a market cap of $179.82 billion, a price-to-earnings ratio of 41.15, a PEG ratio of 4.49 and a beta of 0.83. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $281.70. The firm has a 50 day moving average price of $268.40 and a 200 day moving average price of $260.55.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the prior year, the firm posted $2.02 EPS. The business’s revenue for the quarter was up 3.1% on a year-over-year basis. Sell-side analysts predict that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. The ex-dividend date was Friday, September 27th. Danaher’s payout ratio is currently 18.31%.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. KeyCorp lifted their price target on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. Robert W. Baird reduced their price target on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Evercore ISI raised their price objective on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Wells Fargo & Company assumed coverage on Danaher in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price objective for the company. Finally, Stifel Nicolaus raised their price target on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research report on Wednesday, October 23rd. Seven research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $287.28.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.